RT Journal Article
SR Electronic
T1 Correlation between blood and CSF compartment cytokines and chemokines in subjects with cryptococcal meningitis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.08.20095232
DO 10.1101/2020.05.08.20095232
A1 Okafor, Elizabeth C
A1 Hullsiek, Katherine H
A1 Williams, Darlisha A
A1 Scriven, James E
A1 Rhein, Joshua
A1 Nabeta, Henry W
A1 Musubire, Abdu K
A1 Rajasingham, Radha
A1 Muzoora, Conrad
A1 Schutz, Charlotte
A1 Meintjes, Graeme
A1 Meya, David B
A1 Boulware, David R
YR 2020
UL http://medrxiv.org/content/early/2020/05/12/2020.05.08.20095232.abstract
AB Background Though peripheral blood is a crucial sample to study immunology, it is unclear whether the immune environment in the peripheral vasculature correlates with that at the end-organ site of infection. Utilizing cryptococcal meningitis as a model, we investigated the correlation between serum and cerebrospinal fluid biomarkers over time.Methodology and Principal Findings We analyzed the cerebrospinal fluid and serum of 160 subjects presenting with first episode cryptococcal meningitis for soluble cytokines and chemokines measured by Luminex assay. Specimens were collected at meningitis diagnosis, 1-week, and 2-weeks post cryptococcal diagnosis. We compared paired samples by Spearman correlation and the p-value was set at <0.01. Of the 21 analytes tested at baseline, there was no correlation detected between nearly all analytes. A weak negative correlation was found between serum and cerebrospinal fluid levels of interferon-gamma (Rho= −0.214, p= .007) and interleukin-4 (Rho= −0.232, p=. 003). There was no correlation at 1-week post cryptococcal diagnosis. However, at 2-weeks post diagnosis, there was a weak positive correlation between levels of granulocyte-macrophage colony-stimulating factor (Rho= 0.25, p= .007) between serum and cerebrospinal fluid. No cytokine or chemokine showed consistent correlation overtime.Conclusion and Significance Based on our analysis of 21 biomarkers, serum and cerebrospinal fluid immune responses do not correlate. There appears to be a distinct immune environment in terms of soluble biomarkers in the vasculature versus end-organ site of infection. While this is a model of HIV-related cryptococcal meningitis, we postulate that assuming the blood compartment is representative of the immune function at the end-organ site of infection may not be appropriate.Author Summary In subjects with localized infections, peripheral blood is often used as a surrogate to investigate the immune environment at the end-organ site of infection. Sampling the end-organ site of infection is not routinely performed. The current project serves to fill in the gap of knowledge regarding whether the peripheral blood and end-organ site of infection immune environments correlate. Due to therapeutic lumbar punctures in cryptococcal meningitis, we are able to readily sample the cerebrospinal fluid to investigate compartment specific immune responses by quantifying cytokine and chemokine levels. We determined that there was no correlation between peripheral blood and cerebrospinal fluid cytokine levels. The findings from this works serve to caution the use of peripheral blood as a surrogate for compartment specific immune responses. Though our findings are solely from subjects with cryptococcal meningitis, more research should be performed in other compartment specific infections such as pneumonia, osteomyelitis, or hepatitis for validation. Underestimating or overestimating the activation of the immune response at the end-organ site may impact clinical care and prognosis, especially if immunomodulating agents are being considered as therapy; thus, determining whether peripheral blood and end-organ site of infection immune environments correlate is imperative.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT01075152Funding StatementFinancial Support: This research was supported by the National Institute of Allergy and Infectious Diseases (R01NS086312, U01AI125003, T32AI055433, K23AI138851), National Institute of Neurologic Disorders and Stroke (NINDS) and Fogarty International Center (R01NS086312, K01TW010268, K43TW010718).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll relevant data is included in the manuscript.